Apollo Hospitals Enterprise
- Market cap
- ₹ 1,11,174 Cr.
- P/E
- 55.6x
- P/B
- 11.53x
- 52-week range
- 6,696.5 – 9,070.5
- ROE
- 21%
- ROCE
- 17%
- Dividend yield
- 0.3%
- Debt / equity
- 0.9
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Apollo Hospitals Enterprise Limited is an integrated healthcare company. It is engaged in the business of providing hospital services and selling pharma and wellness products through a network of pharmacies, including the operation of multidisciplinary private hospitals, clinics, diagnostic centers and pharmacies. It is engaged in hospitals and hospitals-based services. The Company's segments include Healthcare Services, Retail Health and Diagnostics, Digital Health and Pharmacy Distribution, and Others. The Retail Health and Diagnostics segment include clinics, diagnostics, Spectra, Cradle, Sugar, Dental and Dialysis business. The Digital Health and Pharmacy Distribution segment is engaged in the business of procurement and distribution of pharmaceuticals, fast-moving consumer goods and private label products business from various services using the digital platform. The Company has approximately 10,100 plus beds across 73 hospitals and 6,600 plus pharmacies.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Apollo Hospitals Enterprise against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)55.6 against a typical 48.9: pricier than most peers (1st = cheapest).24th of 40
- Sales growth+20.6% against a typical +21.1% from a year earlier.18th of 34
- Profit growth+38.3% against a typical +13% from a year earlier.8th of 31
- Share price, 3 months−8.8% against a typical −8.8%.18th of 35
- Size₹ 1,11,173.6 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).1st of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AAA to AA+ by 3 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AAA /[ICRA]A1+ | Stable | 19 Jun 2026 |
| CRISIL | Crisil AA+ | Positive | 29 May 2026 |
| India Ratings | IND AA+; IND A1+ | Positive | 23 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 19 Jun 2026 | Reaffirmed | [ICRA]AAA /[ICRA]A1+ | — | ICRA | ₹ 3,000 Cr. | |
| 29 May 2026 | Reaffirmed | Crisil AA+ | — | CRISIL | ₹ 2,419 Cr. | |
| 18 May 2026 | New rating | [ICRA]AAA /[ICRA]A1+ | — | ICRA | ₹ 3,000 Cr. | |
| 23 Apr 2026 | Rating action | IND AA+ | — | India Ratings | ₹ 2,147 Cr. | |
| 27 Jan 2026 | ▲ Outlook raised | Crisil AA+ Outlook Stable → Positive | — | CRISIL | ₹ 2,419 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 4 Nov 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 12 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 20 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 10 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 6 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 12 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 30 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,847 | 4,851 | 4,944 | 5,086 | 5,589 | 5,527 | 5,592 | 5,842 | 6,304 | 6,477 | 6,606 | 7,044 |
| Expenses | 4,219 | 4,237 | 4,303 | 4,410 | 4,774 | 4,765 | 4,822 | 4,990 | 5,362 | 5,512 | 5,594 | 5,951 |
| Operating Profit | 628 | 614 | 640 | 675 | 816 | 762 | 770 | 852 | 941 | 965 | 1,011 | 1,092 |
| OPM % | 13% | 13% | 13% | 13% | 15% | 14% | 14% | 15% | 15% | 15% | 15% | 16% |
| Other Income | 26 | 29 | 37 | 49 | 44 | 69 | 72 | 54 | 61 | 48 | 54 | 62 |
| Interest | 111 | 113 | 119 | 116 | 118 | 110 | 115 | 108 | 110 | 113 | 119 | 120 |
| Depreciation | 163 | 167 | 190 | 177 | 184 | 185 | 211 | 215 | 218 | 219 | 224 | 235 |
| Profit before tax | 379 | 363 | 368 | 430 | 557 | 536 | 516 | 583 | 675 | 682 | 722 | 799 |
| Tax % | 34% | 30% | 30% | 27% | 29% | 29% | 20% | 24% | 27% | 24% | 24% | 24% |
| Net Profit | 249 | 254 | 258 | 316 | 396 | 379 | 414 | 441 | 494 | 516 | 551 | 610 |
| EPS in Rs | 16.2 | 17.06 | 17.65 | 21.23 | 26.34 | 25.89 | 27.1 | 30.1 | 33.19 | 34.93 | 36.81 | 40.39 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 15%
- 5 Years
- 19%
- 3 Years
- 15%
- TTM
- 17%
- 10 Years
- 23%
- 5 Years
- 76%
- 3 Years
- 32%
- TTM
- 34%
- 10 Years
- 20%
- 5 Years
- 13%
- 3 Years
- 21%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 17%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Apollo Hospitals Enterprise | ₹ 8,200.00 | ₹ 1,11,174 Cr. | 55.6x | 11.5x | 21% | — |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 63.7x | 8.9x | 15.2% | 12.6% |
Management
- Prathap C. Reddy
- Executive Chairman of the Board, Founder
- Preetha Reddy
- Executive Vice Chairman of the Board
- Krishnan Akhileswaran
- Chief Financial Officer
- Sankaranarayan Muthu Krishnan
- Senior Vice President - Finance, Company Secretary
- Sangita Reddy
- Joint Managing Director, Executive Director
- Suneeta Reddy
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.